At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 16 enrolled
Drug / intervention
VX-147drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Open-label, Single-arm, 2-Part Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis
In Brief
A Phase 2 clinical trial evaluating VX-147 for Glomerulosclerosis, Focal Segmental. Completed, enrolled 16 participants across 44 sites in 4 countries.
Detailed Summary
This study will evaluate the efficacy, safety and pharmacokinetics (PK) of VX-147 in participants with apolipoprotein L1 (APOL1)-mediated focal segmental glomerulosclerosis (FSGS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGlomerulosclerosis, Focal Segmental
CountriesFrance, Puerto Rico, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedApr 2020
Enrollment StartJun 2020
Primary CompletionNov 2021
Study CompletionDec 2021
TodayJul 2026
First PostedApr 9, 2020
Enrollment StartJun 8, 2020
Primary CompletionNov 11, 2021
Study CompletionDec 9, 2021
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 6.2 years ago
Interventions
VX-147drug
Tablets for oral administration.